Global Pulmonary Arterial Hypertension (PAH) Therapeutics - Pharmaceuticals

Monday, July 10, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, July 10, 2017 /PRNewswire/ -- This report analyzes the worldwide markets for Pulmonary Arterial Hypertension (PAH)

Therapeutics in US$ Million. The Global market is analyzed by the following Drug Class and Brands: Endothelin Receptor Antagonist (Letairis/Volibris, Macitentan, Thelin, & Tracleer), Prostacyclin and Prostacyclin Analogs (Epoprostenol/Veletri*, Flolan,
Remodulin, Selexipag, Tyvaso, Ventavis, & Orenitram), PDE-5 Inhibitors (Cialis/Adcirca, & Revatio), and Soluble Guanylate Cyclase (sGC) Stimulator (Riociguat). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Read the full report: http://www.reportlinker.com/p04707132/Global-Pulmonary-Arterial-Hypertension-PAH-Therapeutics-Pharmaceuticals.htmlAnnual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 31 companies including many key and niche players such as:- Actelion Pharmaceuticals Ltd.- Bayer AG- Gilead Sciences, Inc.- Pfizer, Inc.- United Therapeutics CorporationRead the full report: http://www.reportlinker.com/p04707132/Global-Pulmonary-Arterial-Hypertension-PAH-Therapeutics-Pharmaceuticals.htmlI. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting LimitationsDisclaimersData Interpretation & Reporting LevelQuantitative Techniques & AnalyticsProduct Definitions and Scope of StudyA. Endothelin Receptor Antagonists (ERAs)B. Prostacyclin and Prostacyclin AnalogsC. Phosphodiesterase type 5 (PDE-5) InhibitorsD. Soluble Guanylate Cyclase (sGC) StimulatorII. EXECUTIVE SUMMARY1. INDUSTRY OVERVIEWPulmonary Arterial Hypertension (PAH) - A PreludeCurrent & Future AnalysisPAH Drugs Market by ClassTable 1: Global PAH Market by Drug Class (2016 & 2018): Percentage Share Breakdown of Sales by Drug Class (includes corresponding Graph/Chart)The PAH ClassificationPH Patient Groupings as per World Health OrganizationClassification of PAH patients as per New York Heart Association (NYHA)Oral Therapies lead the Global PAH Therapeutics MarketTable 2: Global PAH Market by Mode of Drug Usage (2016): Percentage Share Breakdown for Oral, Inhaled, and Injectables (includes corresponding Graph/Chart)Combination Therapy Favored over Monotherapy for PAHPediatric PAH - A Potential Market with Unmet NeedInflammation: New Target for PAH TherapeuticsAging Population & PAHTable 3: Global Aging Population (in Thousands) by Age Group: 1975-2050 (includes corresponding Graph/Chart)Table 4: Global Population by Age-Group: Percentage Change Over the Period 2010-2050 (includes corresponding Graph/Chart)2. COMPETITIVE SCENARIOLeading PlayersTable 5: Leading Drugs for PAH (2016): Percentage Share Breakdown of Revenue by Brand (includes corresponding Graph/Chart)Table 6: Leading Players in the Global PAH Therapeutics Market: Percentage Share Breakdown of Revenues by Company (includes corresponding Graph/Chart)Leading Approved Drugs as Per Mode of AdministrationMajor Drug Brands by ClassProstacyclin receptor agonist/ Prostacyclin AnalogueFlolan (Epoprostenol)Ventavis (Iloprost)Remodulin (Treprostinil)OrenitramTyvasoUptravi (Selexipag)Veletri® (Epoprostenol for Injection)Phosphodiesterase 5 inhibitorRevatioAdcirca (Tadalafil)Endothelin receptor antagonists (ERAs)OpsumitTracleer (Bosentan)Letairis (Ambrisentan)Loss of Market exclusivity Tones Down GrowthPatent Expiry of Leading PAH DrugsOpsumit & Uptravi: Game-changers for ActelionSelexipag - Latest Entrant in PAH TherapeuticsUnited Therapeutics - A Major PlayerGilead SciencesGlaxoSmithKlineBayer3. PAH PIPELINEPulmokine Investigates PDGF Receptor PathwayReata Pharmaceuticals Completes Phase 3 Study for Bardoxolone methylEiger BioPharmaceuticals Commences Phase 2 Trials for BestatinInsmed Investigates INS 1009LTT Bio-Pharma Focuses on LT-2004Ascendis Investigates TransCon Treprostinil in a Phase I trialArena Initiates Phase II Trial for Ralinepeg,TheraSilence nanoparticles Found to Reduce Pulmonary Arterial ThicknessCXA-10 to Undergo Phase II StudyAtu111 Undergoes Preclinical Trial for PHRP5063 - A NCE for PAHSteadyMed to File NDA for Trevyent®Pluristem's PLX-PADSagene Pharmaceuticals, Inc.Select PAH Therapeutics under Pipeline: 20164. PRODUCT OVERVIEWIntroductionPAH SubgroupsPAH Therapeutics TimelineTimeline for PAH TherapeuticsCauses and Development of PAHSymptoms of PAHDiagnosis of PAHIdentification of patients on clinical groundsDetection of PAHEvaluation and classification of PAHOverview of Treatments for PAHTreatments for PAHTreatment Pathways in PAHAn Insight into PAH Drug ClassesProstacyclin Analogs/ProstanoidsEndothelin Receptor Antagonists (ERAs)Phosphodiesterase type 5 (PDE-5) InhibitorsSoluble Guanylate Cyclase (sGC) StimulatorPAH Therapies by ClassProstacyclin Analogs/ProstanoidsEndothelin (ET-1) Receptor AntagonistsPhosphodiesterase-5 (PDE) InhibitorsSoluble Guanylate Cyclase (sGC) StimulatorsNovel Therapies for PAH5. PRODUCT INNOVATIONS & APPROVALSNippon Shinyaku Receives Marketing Approval for UptraviActelion to Initiate Phase III Study for Pediatric Formulation of OpsumitActelion Announces USFDA Approval of UptraviReata Pharmaceuticals' Bardoxolone Methyl Receives Orphan Drug DesignationActelion Receives Approval for Opsumit from Japan's MHLWBayer Healthcare Receives Approval for Adempas from Japan's MHLWSilence Therapeutics Develops Gene Toolkit for PAH ResearchArena Pharmaceuticals' APD811 Receives Orphan Drug Status for PAH TreatmentBayer's Adempas Approved for Two Rare Types of PAHActelion's Opsumit Receives Approval from Australia's TGA6. RECENT INDUSTRY ACTIVITYArena Pharmaceuticals Initiates Phase 2 Clinical Trial for RalinepagGilead Reports Top-Line Phase 2 Results for GS-4997 ( Selonsertib) in Pulmonary Arterial Hypertension (PAH)Gilead Sciences Accelerates its PAH PortfolioMallinckrodt Pharmaceuticals Acquires IkariaSupernus Pharmaceuticals Receives US$2 million Milestone Payment from United TherapeuticsVectura Group plc Acquires Activaero GmbHMast Therapeutics Completes Acquisition of Aires Pharmaceuticals7. FOCUS ON SELECT GLOBAL PLAYERSActelion Pharmaceuticals Ltd (Switzerland)Bayer AG (Germany)Gilead Sciences, Inc. (US)Pfizer, Inc. (US)United Therapeutics Corporation (US)Lung Biotechnology PBC (US)8. GLOBAL MARKET PERSPECTIVETable 7: World Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 8: World Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)Table 9: World 14-Year Perspective for Pulmonary Arterial Hypertension (PAH) Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)Table 10: World Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics by Drugs - Endothelin Receptor Antagonist (ERA) (Letairis/Volibris, Macitentan, & Tracleer), Prostacyclin and Prostacyclin Analogs (Epoprostenol/Veletri, Flolan, Remodulin, Selexipag, Tyvaso, Ventavis and Orenitram), PDE-5 Inhibitors (Cialis/Adcirca & Revatio (Sildenafil)) and Soluble Guanylate Cyclase (sGC) Stimulators (Riociguat) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2018 (includes corresponding Graph/Chart)Table 11: World Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics by Drugs - Endothelin Receptor Antagonist (ERA) (Letairis/Volibris, Macitentan, & Tracleer), Prostacyclin and Prostacyclin Analogs (Epoprostenol/Veletri, Flolan, Remodulin, Selexipag, Tyvaso, Ventavis and Orenitram), PDE-5 Inhibitors (Cialis/Adcirca & Revatio (Sildenafil)) and Soluble Guanylate Cyclase (sGC) Stimulators (Riociguat) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)Table 12: World 10-Year Perspective for Pulmonary Arterial Hypertension (PAH) Therapeutics Market by Drugs - Percentage Breakdown of Dollar Sales for Endothelin Receptor Antagonist (ERA) (Letairis/Volibris, Macitentan, & Tracleer), Prostacyclin and Prostacyclin Analogs (Epoprostenol/Veletri, Flolan, Remodulin, Selexipag, Tyvaso, Ventavis and Orenitram), PDE-5 Inhibitors (Cialis/Adcirca & Revatio (Sildenafil)) and Soluble Guanylate Cyclase (sGC) Stimulators (Riociguat) Markets for Years 2009, 2016 & 2018 (includes corresponding Graph/Chart)III. MARKET1. THE UNITED STATESA.Market AnalysisHigh PAH Incidence: Major Market BoosterHigh Costs: Major Challenge for R&D of PAH TherapeuticsAging Population Statistics: Key Opportunity IndicatorTable 13: Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)Prospective Market for Combination Therapies in the USTable 14: PAH Market in the US (2011): Percentage Share Breakdown by Volume for Class of PAH Patients - Class II, Class III, Class I and Class IV (includes corresponding Graph/Chart)Leading DrugsFDA Approved PAH Drugs in the USProduct LaunchesStrategic Corporate DevelopmentsSelect Key PlayersB.Market AnalyticsTable 15: US Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 16: US Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)2. CANADAMarket AnalysisTable 17: Canadian Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 18: Canadian Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)3. JAPANA.Market AnalysisSelect Approved and Pipeline Drugs in Japanese PAH marketProduct ApprovalLTT Bio-Pharma Co. Ltd.: Key Japan- based PlayerB.Market AnalyticsTable 19: Japanese Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 20: Japanese Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4. EUROPEMarket AnalysisTable 21: European Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics by Geographic Region/Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 22: European Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics by Geographic Region/Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)Table 23: European 14-Year Perspective for Pulmonary Arterial Hypertension (PAH) Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of European Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)4a. FRANCEMarket AnalysisTable 24: French Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 25: French Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4b. GERMANYA.Market AnalysisBayer AG: Key Germany-based PlayerB.Market AnalyticsTable 26: German Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 27: German Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4c. ITALYMarket AnalysisTable 28: Italian Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 29: Italian Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4d. UNITED KINGDOMA.Market AnalysisProduct LaunchStrategic Corporate DevelopmentSilence Therapeutics plc: Key UK-Based PlayerB.Market AnalyticsTable 30: UK Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 31: UK Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4e. SPAINMarket AnalysisTable 32: Spanish Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 33: Spanish Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4f. REST OF EUROPEA.Market AnalysisProduct Launches/DevelopmentsStrategic Corporate DevelopmentSelect Key PlayersB.Market AnalyticsTable 34: Rest of European Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 35: Rest of European Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)5. ASIA-PACIFICMarket AnalysisTable 36: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 37: Asia-Pacific Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)6. LATIN AMERICAMarket AnalysisTable 38: Latin American Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 39: Latin American Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)7. REST OF WORLDMarket AnalysisTable 40: Rest of World Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 41: Rest of World Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)IV. COMPETITIVE LANDSCAPETotal Companies Profiled: 31 (including Divisions/Subsidiaries - 33) The United States (18) Japan (3) Europe (10) - France (1) - Germany (3) - The United Kingdom (3) - Rest of Europe (3) Asia-Pacific (Excluding Japan) (1) Middle East (1)Read the full report: http://www.reportlinker.com/p04707132/Global-Pulmonary-Arterial-Hypertension-PAH-Therapeutics-Pharmaceuticals.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com __________________________Contact Clare: [email protected] US: (339)-368-6001Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/global-pulmonary-arterial-hypertension-pah-therapeutics---pharmaceuticals-300485311.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store